Douglas E. Peterson, DMD, PhD, has served as a consultant for MGI Pharma, Inc., in the past year, after completion of the clinical phase of the study.
Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy†
Version of Record online: 7 DEC 2006
Copyright © 2006 American Cancer Society
Volume 109, Issue 2, pages 322–331, 15 January 2007
How to Cite
Peterson, D. E., Jones, J. B. and Petit, R. G. (2007), Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer, 109: 322–331. doi: 10.1002/cncr.22384
The clinical component of this study was funded by Aesgen, Inc. After completion of the Phase III clinical study, Aesgen, Inc. was acquired by MGI Pharma, Inc. in September 2004. MGI Pharma, Inc. then provided funding for completion of data analyses and related study activities. We thank the clinicians and patients in Russia who participated in the study. We thank Chris L. French, MBA, and Edward C. Shinal, PhD, for significant contributions and Dr. Stephen T. Sonis for expertise in data analysis.
- Issue online: 8 JAN 2007
- Version of Record online: 7 DEC 2006
- Manuscript Accepted: 11 OCT 2006
- Manuscript Revised: 28 SEP 2006
- Manuscript Received: 8 AUG 2006
- 8Kepivance (palifermin) [package insert]. Thousand Oaks, CA: Amgen Inc; 2004–2005.
- 16Pharmacokinetics (PK) of Saforis administered to healthy subjects and stem cell transplant (SCT) patients with WHO grade > 2 oral mucositis (OM) [Abstract 16–115]. Support Care Cancer. 2006; 14: 640., , , , .
- 17A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2005; 36: 611–616., , , et al.
- 22Glutamine as a potential treatment for the prevention of chemotherapy-induced mucositis. J Infus Chemother. 1994; 4: 64–67..
- 26AES-14 facilitates rapid intracellular transport of high levels of L-glutamine in mucosal epithelial cells [Abstract 2410]. Proc Am Soc Clin Oncol. 2000; 19: 612a., , .
- 27Aesgen-14 (uptake-enhanced L-glutamine suspension) reduces severe mucositis in acute radiation model where aqueous L-glutamine suspension is ineffective [Abstract 2861]. Proc Am Soc Clin Oncol. 2002; 21: 261b., .
- 30Phase III study: AES-14 in chemotherapy patients at risk for mucositis [Abstract 2917]. Proc Am Soc Clin Oncol. 2003; 22: 725., .
- 34The design and analysis of clinical experience. New York: John Wiley & Sons; 1986: 275–279..